Skip to content
Order

Cell type guide

CAR-T cells RNA silencing guide

Master RNA silencing in CAR-T cells

Enhance persistence, prevent exhaustion, and optimize manufacturing: all without transfection

CAR-T Viability
Preserved; target-dependent
Expansion Compatible
Yes
Knockdown Efficiency
70-95% knockdown
Scalability
Plates to bioreactors

Why gene silencing enhances CAR-T cells

Chimeric Antigen Receptor (CAR) T cells redirect T cells to target tumor antigens through engineered receptors. A functional CAR consists of an extracellular single-chain variable fragment (scFv) for antigen recognition, a hinge region, a transmembrane domain, one or more costimulatory domains (CD28 or 4-1BB for second-generation CARs), and the CD3ζ signaling domain for T cell activation.

Despite clinical successes in hematologic malignancies, CAR-T cells face critical manufacturing and therapeutic challenges: T cell exhaustion during the 7-14 day expansion phase, transfection-induced toxicity when introducing gene modifications, target antigen-mediated fratricide (particularly for CD7-targeting and CD5-targeting CARs), poor persistence in solid tumor microenvironments, and high commercial pricing per treatment.

AUMsilence sdASO silences a target gene in a primary human T cell, which is the biology a CAR-T keeps. CAR-T cells are engineered T cells that retain core T cell biology, so the gymnotic delivery route, and the activation, proliferation and effector function readouts beside it, are the ones a CAR-T manufacturing workflow already uses. AUMsilence sdASO has been used on immune cells in tumor-microenvironment contexts, including FOXP3 knockdown in regulatory T cells. This transfection-free platform offers a transient, reversible alternative to permanent genome editing for studying gene function in CAR-T exhaustion, persistence, signaling, and tumor interactions. Note: what is described here is read from primary T cell biology. CAR-T-specific optimization and validation are recommended for each target.
The gymnotic delivery mechanism fits AUMsilence sdASO into a CAR-T expansion protocol with no delivery step. No electroporation, no lipofection and no viral transfection are used, so the delivery step brings none of the cell death that CAR-T expansion cannot afford. The transient nature of ASO-mediated silencing suits manufacturing optimization, where a gene is modulated during the 7-14 day expansion phase: checkpoint modulation, exhaustion prevention, fratricide reduction or tumor microenvironment resistance, each resting on T cell mechanisms that operate the same way in a CAR-T.
Scientific rationale: CAR-T cells retain core T-cell biology: they undergo activation through the CAR signaling domain (which mimics TCR signaling), expand via identical cytokine pathways (IL-2, IL-7, IL-15), and exhibit exhaustion through the same transcriptional programs (TOX, NR4A transcription factors, PD-1 upregulation). Gene silencing approaches validated in primary T cells therefore apply directly to CAR-T systems, with the added advantage that CAR-T manufacturing workflows already include ex vivo manipulation steps where gymnotic ASO delivery can be integrated during the 7-14 day expansion phase.
Gymnotic delivery means AUMsilence sdASO is added to the culture medium, with no electroporation, no lipofection and no viral transduction. It fits existing activation, transduction and expansion protocols, at small scale and at large scale.
  • CAR structure: scFv to hinge to transmembrane to costimulatory (CD28/4-1BB) to CD3ζ
  • Manufacturing timeline: activation (Day 0-2) to transduction (Day 2-4) to expansion (Day 4-14)
  • Systematic gene knockdown to discover regulators of CAR-T function
  • Identify therapeutic targets through functional genomics screens
  • Exhaustion during expansion limits CAR-T persistence and efficacy
  • Transfection methods (electroporation/lipofection) cause toxicity during manufacturing
  • Viability is read against the untreated arm, in primary T cells and in CAR-T workflows
  • Compatible with lentiviral/retroviral CAR transduction workflows

Critical challenges in CAR-T cell manufacturing and function

CAR-T cells face unique biological and manufacturing barriers that limit therapeutic efficacy and scalability:

T cell exhaustion during manufacturing

Repeated stimulation during the 7-14 day expansion phase causes progressive upregulation of inhibitory receptors (PD-1, TIM-3, LAG-3) and exhaustion transcription factors (TOX, NR4A1). This exhausted phenotype reduces proliferative capacity, cytokine production (IFN-γ, TNF-α), and cytotoxic function before CAR-T cells even reach the patient. CAR-T cells progressively acquire exhaustion markers during the expansion phase, with the extent varying by CAR design, manufacturing protocol, and T cell activation status. AUMsilence sdASO has been used against FOXP3 in regulatory T cells within tumor microenvironments, which is a different problem from the exhaustion a CAR-T acquires during manufacturing: one is the suppression that surrounds the cell, the other is the program inside it.

High impact

Transfection toxicity in manufacturing workflows

Introducing genetic modifications (checkpoint knockdown, HLA silencing for universal CAR-T) via electroporation or lipofection causes cell death during the critical expansion phase. This toxicity extends manufacturing timelines, reduces yield, and alters T cell phenotype distribution (increased effector memory, reduced central memory). The resulting CAR-T product has compromised persistence potential.

High impact

Target antigen-mediated fratricide

CAR-T cells targeting antigens expressed on normal T cells (CD7 for T-cell acute lymphoblastic leukemia, CD5 for T-cell lymphoma) can undergo fratricide during manufacturing, where CAR-T cells kill each other due to shared antigen expression. This significantly reduces cell expansion and manufacturing yield. CD7-targeting CARs require fratricide-prevention strategies, most commonly CRISPR/Cas9 knockout or base editing of the CD7 gene to permanently eliminate CD7 surface expression. CD5 fratricide varies by CAR design; some CARs achieve expansion via surface downregulation, while others require genetic editing strategies.

High impact

Poor tumor persistence and trafficking in solid tumors

CAR-T cells face immunosuppressive solid tumor microenvironments rich in TGF-β, adenosine, and metabolic stressors. Checkpoint receptor upregulation (PD-1, LAG-3, TIM-3) combined with inadequate tumor infiltration limits efficacy. CAR-T works best in hematologic malignancies, where the tumor cells are accessible, and solid tumors have been harder. Regulatory T cells (Tregs) are key mediators of tumor immunosuppression. In a study using AUMsilence sdASO, an ASO against FOXP3 (the master Treg transcription factor) lowered Treg numbers in human cancer samples by 60%, with intratumoral Tregs more sensitive than those in peripheral blood, and in two mouse tumor models given a murine analogue of it at 50 mg/kg intraperitoneally daily for 14 days, 22% of TC1 and 13.6% of MC38 tumors resorbed completely; the T cells left inside the treated tumors made more perforin and granzyme B (Akimova et al., Frontiers in Immunology, 2024, doi 10.3389/fimmu.2024.1426657).

High impact

Manufacturing scalability and cost

Current autologous CAR-T manufacturing requires individualized processing for each patient: leukapheresis, T cell isolation, activation, viral transduction, expansion (7-14 days), formulation, and cryopreservation. This complex workflow is costly per dose, and manufacturing failures are reported at rates that differ by disease. Allogeneic "off-the-shelf" CAR-T could reduce costs but requires HLA silencing to prevent graft-versus-host disease.

High impact

Cytokine release syndrome (CRS) risk

Rapid CAR-T expansion and activation in vivo triggers massive cytokine release (IL-6, IFN-γ, TNF-α, IL-1), causing potentially fatal systemic inflammation. While manageable with tocilizumab (anti-IL-6R), severe CRS remains a major safety concern limiting CAR-T dosing and accessibility. Reducing CAR-T inflammatory cytokine production without compromising anti-tumor efficacy could improve safety profiles.

Medium impact

Method comparison

Gene silencing methods for CAR-T enhancement
MethodEfficiencyViabilityProsCons
Lipofection (cationic lipid reagents)LowReducedSimple, commercially availableLow efficiency in primary T cells, moderate toxicity, activation-induced cell death, disrupts manufacturing timeline
Electroporation systemsModerate to highReducedModerate to high efficiencySignificant cell death, phenotypic changes (loss of central memory), alters expansion kinetics, expensive
CRISPR/Cas9 (permanent knockout)ReducedPermanent gene knockout, stable phenotypeRequires electroporation (toxicity), off-target mutagenesis risk, complex regulatory path for clinical use, expensive
Viral shRNA (lentiviral integration)HighHigh efficiency, stable knockdownRequires additional viral vector (safety concerns), insertional mutagenesis, GMP production complexity, 2-4 week timeline
AUMsilence sdASO70-95% knockdownPreserved; target-dependentNo transfection, no disruption of the expansion protocol, scalable (add to medium), transient knockdown, appropriate for optimization; the central memory phenotype is read against the untreated armTransient knockdown (appropriate for manufacturing optimization; re-dose for sustained effect)

AUMsilence sdASO protocols for CAR-T cell enhancement

Optimized protocols for integrating gene silencing into CAR-T manufacturing workflows. No transfection reagent and no equipment are required.

Quick start protocol (all CAR-T applications)

  1. 01Activate T cells (anti-CD3/CD28 beads, 1:1 ratio) at 1 × 10⁶ cells/mL in RPMI + 10% FBS + IL-2 (50-100 U/mL)
  2. 02At Day 2-3 post-activation, add AUMsilence sdASO directly to culture at 10 μM (no transfection reagent)
  3. 03Proceed with lentiviral or retroviral CAR transduction at Day 3-4 (ASO does not interfere)
  4. 04Continue expansion for 7-10 days; re-dose ASO every 3 to 5 days if sustained knockdown is needed
  5. 05Validate knockdown by qRT-PCR (48-72h after treatment) and flow cytometry (72-96h after treatment); confirm CAR expression maintained

Cell-type-specific protocols

Pre-transduction gene knockdown (checkpoint knockdown)

Silence inhibitory receptors before CAR transduction, with persistence as the readout

  1. Step 1: T cell isolation and activation

    Isolate CD3+ T cells from PBMCs (negative selection). Activate with anti-CD3/CD28 magnetic beads (1:1 bead-to-cell ratio) in complete RPMI + 10% FBS + IL-2 (50-100 U/mL). Seed at 1 × 10⁶ cells/mL in T-cell culture flasks or gas-permeable bioreactors.

    Materials: RPMI-1640, FBS, IL-2, anti-CD3/CD28 magnetic activation beads

    Note: Activation primes T cells for both ASO uptake and viral transduction

    Timing: Day 0-1

  2. Step 2: AUMsilence sdASO treatment (pre-transduction)

    At Day 2-3 post-activation, add AUMsilence sdASO targeting PD-1 (PDCD1), CTLA-4, or LAG-3 at 10 μM directly to culture. For example: targeting PD-1 to create checkpoint-resistant CAR-T. No media change required. Beads remain in culture.

    Materials: AUMsilence sdASO (1 mM stock in nuclease-free water)

    Note: Pre-transduction knockdown reduces the receptor before the CAR is introduced

    Timing: Day 2-3

  3. Step 3: CAR transduction

    At Day 3-5 (24-72h post-ASO treatment), transduce with lentiviral or retroviral CAR vector at MOI 3-10. Delayed timing allows checkpoint knockdown to take effect before CAR introduction. ASOs target endogenous transcripts, not the viral vector, so AUMsilence sdASO is added around the transduction. Continue culture with IL-2.

    Materials: CAR lentiviral/retroviral vector, hexadimethrine bromide (optional, 8 μg/mL)

    Note: Read transduction efficiency and CAR expression at Day 7-10 against the untreated arm.

    Timing: Day 3-5

  4. Step 4: CAR-T expansion

    Expand CAR-T cells for 7-10 additional days. Monitor cell density (split to 0.5-1 × 10⁶/mL when exceeding 2 × 10⁶/mL). Re-dose AUMsilence sdASO every 3 to 5 days if sustained knockdown is desired.

    Materials: Complete RPMI + IL-2, larger culture vessels as needed

    Note: Read proliferation against the untreated arm of the same manufacturing run

    Timing: Day 4-14

  5. Step 5: Validation and functional testing

    Validate knockdown: qRT-PCR for target mRNA, expect 70-95% knockdown; lower values common due to rapid CAR-T division diluting ASO. Flow cytometry for protein (PD-1, CTLA-4 surface expression). Confirm CAR expression by Protein L or anti-idiotype staining (expect no reduction). Perform cytotoxicity assays against target cells.

    Materials: Flow cytometry antibodies, tumor target cells, cytotoxicity assay reagents

    Note: CAR+ percentage should be identical to the control arm; read cytotoxicity against that arm.

    Timing: Day 10-14

Post-transduction enhancement (exhaustion prevention)

Prevent exhaustion in already-transduced CAR-T cells during expansion

  1. Step 1: Standard CAR-T manufacturing start

    Activate T cells (Day 0-2) and transduce with CAR vector (Day 2-4) according to standard protocol. Begin expansion in complete RPMI + IL-2.

    Materials: Standard CAR-T manufacturing reagents

    Note: Follow established activation and transduction protocols

    Timing: Day 0-4

  2. Step 2: AUMsilence sdASO treatment (post-transduction)

    At Day 5-7 post-transduction, when CAR-T cells are actively expanding, add AUMsilence sdASO targeting TOX (exhaustion driver) or NR4A1 (exhaustion mediator) at 10 μM. TOX and NR4A1 drive the exhaustion program that the expansion phase accelerates.

    Materials: AUMsilence sdASO targeting TOX, NR4A1, NR4A2, or NR4A3

    Note: Post-transduction timing ensures CAR expression established before exhaustion prevention

    Timing: Day 5-7

  3. Step 3: Continued expansion

    Continue CAR-T expansion for 7-10 additional days. Re-dose AUMsilence sdASO every 3 to 5 days to maintain knockdown throughout expansion. Read the exhaustion markers (PD-1, TIM-3, LAG-3) by flow cytometry against the untreated arm.

    Materials: Complete RPMI + IL-2

    Note: TOX/NR4A1 knockdown prevents upregulation of multiple exhaustion markers

    Timing: Day 7-14

  4. Step 4: Functional validation

    Compare exhaustion marker expression (PD-1, TIM-3, LAG-3, TOX) between ASO-treated and control CAR-T. Measure proliferation, cytokine production (IFN-γ, TNF-α), and cytotoxicity against the same control.

    Materials: Flow cytometry panel (exhaustion markers), ELISA kits, target tumor cells

    Note: Persistence is read in a long-term co-culture against the untreated arm

    Timing: Day 12-14

Fratricide prevention (target antigen knockdown)

Research approach for CD7-CAR or CD5-CAR manufacturing using transient antigen knockdown

  1. Step 1: T cell activation

    Activate CD3+ T cells with anti-CD3/CD28 beads as described above. For CD7-targeting CARs (T-ALL treatment), CD7 is expressed on T cells themselves, causing fratricide.

    Materials: Standard activation reagents

    Note: CD7 and CD5 are normally expressed on T cells; must be silenced to prevent self-killing

    Timing: Day 0-1

  2. Step 2: Target antigen knockdown (pre-transduction)

    At Day 2-3 post-activation, add AUMsilence sdASO targeting CD7 (for CD7-CAR) or CD5 (for CD5-CAR) at 10 μM. Allow 24-72 hours for knockdown before transduction.

    Materials: AUMsilence sdASO anti-CD7 or anti-CD5

    Note: Critical: knockdown must occur before CAR transduction to prevent immediate fratricide

    Timing: Day 2-3

  3. Step 3: Validation of antigen knockdown

    At 48-72h post-ASO treatment, validate CD7 or CD5 knockdown by flow cytometry. Proceed to transduction only if knockdown confirmed.

    Materials: Flow cytometry antibodies (anti-CD7 or anti-CD5)

    Note: Insufficient knockdown results in fratricide and manufacturing failure

    Timing: Day 4-5

  4. Step 4: CAR transduction and expansion

    Transduce with CD7-CAR or CD5-CAR lentiviral vector while the target antigen is knocked down. Expand for 7-10 days with IL-2. Re-dose AUMsilence sdASO every 3 to 5 days to maintain target antigen suppression.

    Materials: CD7-CAR or CD5-CAR lentiviral vector

    Note: Monitor CD7/CD5 expression; should remain <20% of baseline to prevent fratricide

    Timing: Day 5-14

  5. Step 5: CAR-T validation

    Confirm CAR expression (Protein L staining), sustained CD7/CD5 knockdown, and cytotoxicity against CD7+ or CD5+ tumor targets. CAR-T cells should kill tumor targets but not each other.

    Materials: Protein L, tumor cell lines (Jurkat for CD7, T-cell lymphoma lines for CD5)

    Note: Whether transient knockdown prevents fratricide well enough for expansion is a research question

    Timing: Day 14

Universal CAR-T development (HLA knockdown)

Research approach for creating allogeneic off-the-shelf CAR-T (research use only)

  1. Step 1: T cell isolation and activation

    Isolate and activate healthy donor T cells. For universal CAR-T, goal is to eliminate HLA Class I expression to prevent host rejection.

    Materials: Standard activation reagents

    Note: Research application only: not for clinical use. Extensive safety validation, regulatory approval, and GMP production required before any clinical consideration

    Timing: Day 0-2

  2. Step 2: HLA class I knockdown (B2M)

    At Day 2-3, add AUMsilence sdASO targeting B2M (beta-2 microglobulin, required for HLA Class I surface expression) at 10 μM. This reduces HLA-A, HLA-B, HLA-C presentation. Critical: this creates NK cell susceptibility (see protocol note above).

    Materials: AUMsilence sdASO anti-B2M

    Note: B2M knockdown reduces HLA Class I without permanent genome editing, but creates "missing-self" NK cell recognition. Cells are killed by NK cells unless additional NK evasion strategies are implemented.

    Timing: Day 2-3

  3. Step 3: CAR transduction

    Transduce with CAR vector at Day 3-4. Expand with IL-2 while maintaining B2M knockdown (re-dose every 3 to 5 days).

    Materials: CAR lentiviral vector

    Note: Warning: HLA-negative CAR-T avoid host T cell recognition but are highly susceptible to NK cell killing unless HLA-E or other NK inhibitory ligands are co-expressed. For research use only. Not for use in diagnostic or therapeutic procedures.

    Timing: Day 3-14

  4. Step 4: Validation and NK evasion assessment

    Confirm B2M knockdown and loss of HLA-A/B/C surface expression by flow cytometry. Test for allo-reactivity in mixed lymphocyte reactions. Critical: perform NK cell cytotoxicity assays to assess susceptibility. HLA-negative CAR-T are killed by NK cells unless additional modifications (HLA-E or CD47 overexpression) are implemented.

    Materials: Flow antibodies (B2M, HLA-A/B/C), allogeneic PBMCs, primary NK cells or NK-92 cells for cytotoxicity assays

    Note: This incomplete protocol produces CAR-T cells that evade host T cell recognition but are killed by NK cells. For functional universal CAR-T, co-expression of HLA-E or CD47 is mandatory. For research use only. Not for use in diagnostic or therapeutic procedures. Extensive safety validation is required.

    Timing: Day 14

Essential controls for CAR-T enhancement

  • Untreated CAR-T cells: Baseline CAR-T phenotype, expansion, and function
    Activate, transduce, and expand identically without ASO addition
  • Non-targeting control ASO: Control for ASO-related effects on CAR-T manufacturing
    Use AUM non-targeting control at same concentration (10 μM) and timing as experimental ASO
  • Mock-transduced controls: Separate ASO effects on T cells from CAR-specific effects
    Treat T cells with ASO but skip CAR transduction; validates ASO effects independent of CAR
  • CAR expression verification: Ensure ASO does not affect CAR transgene expression
    Stain with Protein L or anti-idiotype antibody; CAR+ percentage should match untreated

Optimization strategies for CAR-T applications

Timing in manufacturing workflow

Recommendation: Pre-transduction (Day 2-3) for checkpoint knockdown and fratricide prevention. Post-transduction (Day 5-7) for exhaustion prevention.

Rationale: Pre-transduction establishes phenotype before CAR introduction. Post-transduction ensures CAR expression established before modifying T cell state.

ASO concentration

Recommendation: The recommended working range is 5-20 μM, with a starting concentration of 10 μM.

Rationale: CAR-T cells undergo rapid proliferation during expansion (doubling every 24-48h), which dilutes ASO. Higher concentrations or re-dosing compensates.

Duration and re-dosing

Recommendation: A single dose holds the knockdown for 3 to 5 days. Re-dose at that interval during expansion for sustained effect throughout manufacturing.

Rationale: Rapid cell division during CAR-T expansion dilutes ASO, so a culture doubling every 24-48h takes the short end of that interval. Re-dosing maintains knockdown throughout 7-14 day manufacturing timeline.

Combination with CAR transduction

Recommendation: AUMsilence sdASO does not interfere with lentiviral or retroviral transduction. Can be added before, during, or after transduction.

Rationale: ASOs target endogenous transcripts, not the viral vector or the CAR transgene. Read transduction efficiency and CAR expression against the untreated arm.

Multi-target knockdown

Recommendation: Can combine multiple ASOs (e.g., PD-1 + LAG-3 dual checkpoint knockdown). Keep the combined concentration within 5-20 μM.

Rationale: Combinatorial checkpoint blockade may provide additive benefits. Limit total ASO to avoid non-specific effects.

ASO sequence selection

Recommendation: Design and test 3-5 ASOs targeting different regions. Select sequence with highest knockdown and no impact on CAR expression.

Rationale: Knockdown efficiency varies by target site. Testing several sequences identifies the most effective one and confirms specificity.

Troubleshooting

Low knockdown in CAR-T cells (<50%)

  • Re-dose AUMsilence sdASO at the short end of 3 to 5 days during rapid expansion phases
  • Increase concentration within 5-20 μM for highly stable targets
  • Add ASO earlier (Day 2-3 vs. Day 5-7)
  • Test positive control (GAPDH knockdown) to verify ASO activity
  • Design new ASO targeting different region of same transcript

Reduced CAR expression after ASO treatment

  • BLAST ASO sequence against CAR construct; verify no complementarity
  • Test independent ASO sequences targeting different regions of endogenous gene
  • Include CAR expression controls (Protein L staining) in all experiments
  • If persistent, redesign ASO to avoid any similarity to CAR sequence

Poor CAR-T expansion after treatment

  • Expected if targeting survival/proliferation genes; some reduction acceptable
  • Reduce ASO within 5-20 μM and include non-targeting control
  • Verify bead-to-cell ratio (1:1) and IL-2 concentration (50-100 U/mL)
  • Include viability staining

Fratricide still occurs despite antigen knockdown

  • Validate >80% antigen knockdown by flow before CAR transduction
  • Add ASO at Day 2-3 (pre-transduction), not post-transduction
  • Re-dose every 3 to 5 days to maintain antigen suppression
  • Consider a higher concentration within 5-20 μM for this application

Inconsistent results across CAR-T manufacturing runs

  • Standardize activation protocol (same beads, same timing for all donors)
  • Use n≥3 donors for statistical validation
  • Establish one re-dosing schedule at 3 to 5 days and keep it the same across runs
  • Monitor cell density and split consistently (maintain 0.5-1.5 × 10⁶/mL)

Validation methods for CAR-T enhancement

Validation covers knockdown, CAR expression, cytotoxicity, cytokine production, proliferation and exhaustion markers.

Knockdown validation (qRT-PCR and flow cytometry)

Purpose: Confirm target gene silencing at mRNA and protein levels
Protocol: For mRNA: Extract RNA at 48-72h post-ASO treatment, perform qRT-PCR with target-specific primers, normalize to GAPDH/ACTB. For protein: Surface markers by flow cytometry at 72-96h (PD-1, CTLA-4, CD7, CD5, etc.), intracellular proteins by fix/perm staining (TOX, NR4A1, etc.). Include viability dye (7-AAD or Live/Dead Aqua).
Expected results: 70-95% knockdown, measured as mRNA reduction by qRT-PCR and varying with target gene stability, expression level and cell division rate. Protein reduction by flow cytometry (MFI shift for surface markers, depending on protein half-life). Viability is read with the viability dye in the same panel. Results vary significantly between targets, so each gene needs its own validation.
Tips: For surface markers, use median fluorescence intensity (MFI) comparison rather than percentage positive (some checkpoints have bimodal expression). For transcription factors (TOX, NR4A1), fix/permeabilize and use validated intracellular antibodies.

CAR expression analysis

Purpose: Ensure ASO treatment does not affect CAR transgene expression
Protocol: Stain CAR-T cells at Day 7-10 with Protein L conjugate (binds kappa light chains in scFv) or CAR-specific detection reagent (anti-idiotype antibody, biotinylated antigen). Analyze by flow cytometry. Compare CAR+ percentage and MFI between ASO-treated and untreated.
Expected results: CAR+ percentage should be identical between treated and control. No reduction in CAR MFI.
Tips: Critical validation: if CAR expression reduced, ASO has off-target effect on viral promoter or CAR sequence. BLAST ASO against CAR construct to verify no complementarity. Test alternative ASO sequences.

Cytotoxicity assays (tumor killing)

Purpose: Measure tumor killing against the control arm
Protocol: Co-culture CAR-T cells with tumor target cells (expressing CAR antigen) at various effector-to-target (E:T) ratios (1:1, 3:1, 10:1). Measure target cell lysis at 4h, 18h, 48h by: (1) LDH release assay, (2) flow cytometry-based viability (label targets with fluorescent cell tracking dye, measure 7-AAD uptake), (3) impedance-based real-time cell analyzer, or (4) luciferase-expressing targets (luminescence reduction).
Expected results: read specific lysis at the lower E:T ratios (1:1, 3:1) against untreated CAR-T from the same manufacturing run, where a difference is least likely to be hidden by a ceiling effect. Serial rechallenge reads persistence.
Tips: Include serial rechallenge: after initial 48h co-culture, harvest CAR-T, wash, and re-plate with fresh tumor targets, and read how many rounds of killing each arm sustains. This mimics repeated antigen encounter in vivo.

Cytokine production analysis

Purpose: Assess CAR-T effector function and inflammatory profile
Protocol: Stimulate CAR-T cells with tumor targets (4h for TNF-α/IFN-γ, 24h for IL-2) or plate-bound anti-CAR antibody. Collect supernatants and measure cytokines by ELISA or multiplex cytokine assay: IFN-γ, TNF-α, IL-2, granzyme B, perforin. Normalize to CAR-T cell number.
Expected results: read IFN-γ and TNF-α against untreated CAR-T from the same run. Where the cytokine's own gene is the target, as in a TNF-α knockdown for CRS work, that fall is the knockdown read at the protein.
Tips: Measure both Th1 cytokines (IFN-γ, TNF-α) and cytotoxic molecules (granzyme B, perforin). If testing CRS mitigation strategies, include IL-6 (even though primarily macrophage-derived, CAR-T contribute). Compare cytokine profile to killing capacity; goal is maintain efficacy while reducing inflammatory cytokines.

Proliferation and expansion assays

Purpose: Measure CAR-T expansion against the control arm
Protocol: Monitor cell counts daily during expansion (Days 0-14). Calculate population doublings. For proliferation tracking: label with CFSE or violet-fluorescent cell tracking dye at Day 0, stimulate with beads or tumor targets, analyze CFSE dilution by flow at 72-96h. For cell cycle: stain with Ki67 (proliferation marker) and DAPI (DNA content), identify G0/G1 vs. S/G2/M phases.
Expected results: read the population doublings, the CFSE dilution and the Ki67+ fraction against untreated CAR-T from the same run.
Tips: TOX and NR4A1 act on the exhaustion program itself, while PD-1 and CTLA-4 carry a signal that matters most on repeated antigen encounter, so read expansion during manufacturing and persistence on rechallenge separately, each against the control arm.

Exhaustion marker profiling

Purpose: Read the exhaustion phenotype during manufacturing against the control arm
Protocol: Multi-color flow cytometry panel at Day 7, 10, 14 of manufacturing. Stain for: PD-1, TIM-3, LAG-3, TIGIT (surface checkpoints), CD39 (exhaustion marker), TOX (intracellular transcription factor). Also include memory markers: CD45RA, CD45RO, CD62L, CCR7 to assess memory phenotype distribution.
Expected results: TOX and NR4A1 drive the exhaustion program that raises PD-1, TIM-3 and LAG-3 during expansion. Read those three, the PD-1+ TIM-3+ double-positive fraction, and the CD45RO+ CD62L+ CCR7+ central memory fraction against untreated CAR-T from the same run.
Tips: Look for co-expression of multiple checkpoints (e.g., PD-1+ TIM-3+ LAG-3+ triple-positive = severe exhaustion); read that subset against the control arm. Also assess TOX mean fluorescence intensity (MFI); even if percentage TOX+ unchanged, MFI reduction indicates successful knockdown.

In vivo tumor models

Purpose: Validate CAR-T persistence and anti-tumor efficacy in vivo
Protocol: Establish human tumor xenografts in immunodeficient mice. Inject CAR-T cells IV or intra-tumorally. Monitor tumor burden (bioluminescence if tumor is luciferase+, or caliper measurements). Track CAR-T persistence: collect peripheral blood, stain for human CD3 and CAR (Protein L), quantify by flow cytometry. Assess survival (Kaplan-Meier curves).
Expected results: read tumor burden, survival, and CAR-T persistence in blood and tumor at Days 7, 14 and 21 after infusion, each against the arm given untreated CAR-T from the same run.
Tips: In vivo validation is gold standard but resource-intensive. Prioritize after the in vitro readouts are in. Most valuable for exhaustion prevention and tumor microenvironment resistance strategies (TGFβR2 knockdown). Include tumor rechallenge experiments: treat tumor, achieve remission, re-inject tumor cells; test if CAR-T maintain memory and rapid response.

Transcriptomics and epigenomics for mechanism discovery

Purpose: Identify genome-wide changes induced by gene knockdown to understand molecular mechanisms
Protocol: Bulk RNA-seq: Extract RNA from ASO-treated vs control CAR-T at functional timepoints (Day 7, 10, 14 post-transduction). Perform RNA-seq (>20M reads/sample, biological triplicates). Analyze differential gene expression (DESeq2, edgeR), pathway enrichment (GSEA, Reactome), and exhaustion/memory signatures. Single-cell RNA-seq: Use single-cell RNA sequencing platform. Capture 5,000-10,000 cells per condition. Cluster CAR-T subpopulations, perform trajectory analysis to track differentiation, identify knockdown-sensitive vs knockdown-resistant cell states. ATAC-seq: Map chromatin accessibility on 50,000 CAR-T cells per condition. Identify differentially accessible regions, perform motif enrichment to predict transcription factor activity. Reveals how gene knockdown alters chromatin landscape.
Expected results: TOX sits upstream of the exhaustion signature (PD-1, LAG-3, HAVCR2, ENTPD1) and NR4A1 acts on the apoptosis pathways, the BCL2 family among them, so read those signatures and the chromatin accessibility at the exhaustion loci against untreated CAR-T. A compensatory rise in another checkpoint is one of the things this readout is for, and single-cell sequencing is what resolves a subpopulation that bulk sequencing averages away.
Tips: Perform RNA-seq at multiple timepoints to capture dynamic responses. Include dose-response (partial vs complete knockdown). Combine RNA-seq with ATAC-seq to link gene expression changes with chromatin remodeling. Use single-cell RNA-seq to identify rare populations that may be masked in bulk RNA-seq.

Proteomics and phosphoproteomics for signaling pathway mapping

Purpose: Validate ASO specificity, confirm protein-level knockdown, and map downstream signaling changes
Protocol: Mass spectrometry proteomics: Use TMT or SILAC labeling for quantitative proteomics. Compare protein abundance in ASO-treated vs control CAR-T. Confirms on-target protein reduction (should match mRNA knockdown at 48-72h). Phosphoproteomics: Enrich for phosphopeptides (TiO2 or IMAC), perform LC-MS/MS. Map phosphorylation changes in signaling pathways (CAR signaling, MAPK, PI3K/AKT, NFκB). Stimulate with CAR antigen for 5-15 minutes before lysis to capture activation-dependent phosphorylation. Immunoblotting validation: Confirm key protein changes and pathway alterations (phospho-ERK, phospho-AKT, phospho-S6) by Western blot.
Expected results: Protein reduction at 72-96h after treatment, slower and smaller than the mRNA change because of protein half-life. PD-1 dampens proximal CAR signaling, so read phospho-ERK and phospho-AKT on CAR stimulation against untreated CAR-T, and read the exhaustion-associated proteins where TOX is the target. The same comparison is what would show an unexpected off-target protein.
Tips: Proteomics is expensive; prioritize for key mechanistic studies or publication-quality validation. Phosphoproteomics requires rapid sample processing (< 5 min from stimulation to lysis) to preserve phosphorylation state. Include both unstimulated and CAR-antigen-stimulated conditions to map activation-dependent signaling changes. Compare knockdown effects on basal vs activated signaling.

Metabolomics and metabolic flux analysis

Purpose: Understand how gene knockdown affects CAR-T metabolism and bioenergetics
Protocol: Extracellular flux analysis: Measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in real-time. Perform mitochondrial stress test (oligomycin, FCCP, rotenone/antimycin A) to assess oxidative phosphorylation capacity and glycolytic reserve. LC-MS metabolomics: Extract metabolites from CAR-T cells at peak expansion (Day 10). Quantify glycolytic intermediates, TCA cycle metabolites, amino acids, nucleotides, and lipids. 13C-isotope tracing: Culture CAR-T with 13C-glucose or 13C-glutamine, perform LC-MS to track carbon incorporation into metabolic pathways. Reveals glucose vs glutamine utilization.
Expected results: GLUT1 and HK2 carry glycolytic flux and mTOR drives both glycolysis and oxidative phosphorylation, so knocking one down is read as a fall in ECAR and lactate, or in both rates, against untreated CAR-T. A memory T cell runs a higher OCR to ECAR ratio than an effector, so that ratio is the readout where exhaustion is the target. Isotope tracing is what says whether the carbon source shifted.
Tips: Extracellular flux analysis requires 50,000-100,000 cells per well; plan cell numbers accordingly. Normalize all metabolic measurements to cell number (use CyQUANT or protein quantification). Perform metabolomics at multiple timepoints (Days 7, 10, 14) to capture metabolic transitions during expansion. Combine with functional assays; correlate metabolic profile with proliferation, cytokine production, cytotoxicity.

CRISPR validation screens for target prioritization

Purpose: Use transient ASO knockdown to prioritize targets for permanent CRISPR knockout
Protocol: First, perform ASO-based functional screen (50-100 genes in arrayed format, measure exhaustion markers, cytotoxicity, proliferation). Identify top hits (genes whose knockdown significantly improves CAR-T function). Second, validate top 5-10 hits using independent ASO sequences (confirm reproducibility). Third, perform CRISPR knockout of validated targets using electroporation of Cas9 RNP. Compare transient ASO knockdown phenotype to permanent CRISPR knockout. Prioritize targets where both methods show concordant improvements.
Expected results: the screen returns the genes whose knockdown moves the readouts above, which is what the arrayed format is for. CRISPR validation confirms some of those hits and not others, because a permanent knockout can show a different phenotype through compensation or developmental effects. Concordant hits become high-confidence targets for a permanent knockout with CRISPR.
Tips: This workflow leverages ASO speed and safety for discovery, then validates the hits with CRISPR where a permanent knockout is wanted. ASO screening is 5-10x faster than CRISPR screening (no guide RNA optimization, no electroporation optimization, no off-target screening required upfront). Use ASO dose-response to mimic partial vs complete knockout; helps predict CRISPR heterozygous vs homozygous knockout phenotypes. Include both ASO and CRISPR controls in final validation experiments.

Imaging-based functional assays for high-content screening

Purpose: Visualize CAR-T-tumor interactions and quantify functional outputs at single-cell resolution
Protocol: Live-cell imaging cytotoxicity: Label tumor targets with far-red fluorescent cell tracking dye, CAR-T with GFP or live-cell dye. Co-culture in multi-well plates, image every 30-60 minutes using automated microscopy system. Quantify tumor cell killing kinetics, CAR-T migration, serial killing events (one CAR-T killing multiple tumor cells). Immunofluorescence analysis: Fix CAR-T at various timepoints, stain for exhaustion markers (PD-1, TIM-3, TOX), proliferation (Ki67), activation (phospho-ERK, phospho-S6). Image using high-content imager, quantify at single-cell level. 3D tumor spheroid infiltration: Generate tumor spheroids (hanging drop or ultra-low attachment), add CAR-T, image spheroid penetration over 24-72h. Measure CAR-T distribution (surface vs core infiltration).
Expected results: read how long serial killing is sustained against untreated CAR-T in the same field, the nuclear TOX and the surface PD-1 and TIM-3 by image, and how far into a spheroid the CAR-T travel. TGF-β signals through TGFβR2 and the spheroid's interior is where that signal is strongest, which is what makes penetration the readout there. Imaging resolves the cell-to-cell spread that a bulk assay averages away.
Tips: Imaging assays suit kinetic analysis: capture dynamic processes over hours to days. Use automated analysis pipelines (CellProfiler, Harmony software) to handle large image datasets. Image-based assays reveal heterogeneity masked in bulk assays: e.g., identify rare high-performing CAR-T subsets, measure cell-to-cell variation in exhaustion markers. Combine with live-cell reporters (e.g., GFP-TOX fusion protein) to track gene expression dynamics in real-time.

Critical controls for CAR-T validation

  • Untreated CAR-T cells: Baseline CAR-T function and expansion
    Activate, transduce, and expand CAR-T identically to experimental group without ASO addition. This is the gold standard comparison for all functional assays.
  • Non-targeting control ASO: Control for non-specific ASO effects on CAR-T biology
    Use AUM non-targeting control ASO at same concentration (10 μM) and timing as experimental ASO. Verifies that phenotypic changes are target-specific, not ASO-related.
  • Mock-transduced T cells + ASO: Separate ASO effects on T cells from CAR-specific effects
    Treat T cells with ASO but skip CAR transduction. Validates that ASO effects (e.g., checkpoint knockdown) occur in T cells independent of CAR expression.
  • CAR-T without ASO, stimulated with target: Baseline CAR-T exhaustion kinetics
    Co-culture untreated CAR-T with tumor targets for extended periods (7-14 days with weekly target replenishment). Measure progressive exhaustion (PD-1, TIM-3, LAG-3 upregulation, loss of killing). Compare to ASO-treated CAR-T in same assay.
  • Dose-response verification: Confirm concentration-dependent knockdown and optimal dosing
    Test minimum 3 concentrations (e.g., 5 μM, 10 μM and 20 μM AUMsilence sdASO). Knockdown efficiency should correlate with concentration. Validate that 10 μM is in linear range (not saturated or insufficient). Essential for ruling out off-target effects and optimizing protocol.
  • Independent ASO verification: Confirm target specificity with second ASO sequence
    Design 3-5 ASOs targeting different regions of same mRNA. Test all sequences and select top 2 performers. Validate that independent ASO sequences produce concordant phenotypes (improved killing, reduced exhaustion, etc.). This is gold standard for confirming on-target effects and eliminating sequence-specific artifacts.

Best practices

  • Use biological triplicates (n=3 independent CAR-T manufacturing runs, ideally different donors)
  • Validate knockdown at both mRNA (qRT-PCR, 48-72h after treatment) and protein (flow cytometry, 72-96h) levels
  • Always confirm CAR expression is unaffected (Protein L staining); critical QC checkpoint
  • Include serial tumor rechallenge assays to test CAR-T persistence (mimics repeated antigen encounter in vivo)
  • For functional validation, use low E:T ratios (1:1 or 3:1) where differences are most apparent
  • Monitor exhaustion marker co-expression (PD-1+ TIM-3+ LAG-3+ triple-positive) as sensitive exhaustion metric
  • Report CAR-T viability, expansion fold-change, and memory phenotype distribution in all studies
  • Compare to literature benchmarks for CAR-T expansion (6-10 population doublings over 14 days is typical)

Frequently asked questions

Is AUMsilence sdASO compatible with CAR-T expansion workflows?
Yes. AUMsilence sdASO integrates with a standard CAR-T expansion protocol: add it to the culture medium at the timepoints above (Day 2-3 for pre-transduction applications, Day 5-7 for post-transduction). No equipment, no protocol modification and no additional step is required. Compatible with both lentiviral and retroviral CAR transduction. Read activation (anti-CD3/CD28 beads), transduction efficiency and expansion kinetics against the untreated arm. Scales from research (24-well plates) to larger formats (gas-permeable bioreactors, automated cell processing systems).
What grade are AUMsilence sdASOs?
AUMsilence sdASOs are research-grade reagents, made for preclinical CAR-T research and for optimizing an expansion protocol at the bench. AUM BioTech supplies them for research use and offers no material and no documentation for any other use.
Does ASO treatment affect CAR transgene expression?
No. AUMsilence sdASOs are designed to target endogenous human genes (PD-1, TOX, CD7, etc.), not the CAR transgene introduced by viral vector. CAR expression driven by constitutive viral promoters (EF1α, PGK, SFFV) is unaffected. Critical: always validate CAR expression by flow cytometry (Protein L or anti-idiotype staining) post-treatment. CAR+ percentage and mean fluorescence intensity should be identical to untreated controls. If CAR expression reduced, this indicates off-target ASO effect; BLAST ASO sequence against CAR construct and redesign.
How do I prevent fratricide in CD7-targeting CAR-T cells?
CD7 is expressed on both T-ALL tumor cells (target) and normal T cells (CAR-T themselves), causing fratricide during manufacturing. Important research disclaimer: Transient ASO-mediated CD7 knockdown for fratricide prevention represents a research hypothesis that has not been validated in published CAR-T manufacturing studies. All successful CD7-CAR-T products to date use permanent CRISPR/Cas9 knockout or base editing to eliminate CD7 expression. Research protocol: (1) Activate T cells (Day 0-2), (2) Add AUMsilence sdASO anti-CD7 at 10 μM on Day 2-3 (pre-transduction), (3) Validate >80% CD7 knockdown by flow cytometry at Day 4-5, (4) only if knockdown confirmed, proceed with CD7-CAR transduction, (5) Expand CAR-T with ASO re-dosing every 3 to 5 days to maintain CD7 suppression throughout manufacturing. This approach requires extensive validation including demonstration of sustained CD7 suppression, CAR-T expansion comparable to non-fratricide-prone CARs, and in vivo efficacy studies before any clinical consideration. Same strategy applies to CD5-CAR for T-cell lymphoma.
Can I knock down multiple genes simultaneously in CAR-T?
Yes. Multi-gene knockdown enables combinatorial enhancement strategies. Examples: (1) PD-1 + LAG-3 dual checkpoint knockdown, (2) TOX + TGFβR2 for exhaustion prevention + tumor microenvironment resistance, (3) CD7 + PD-1 for fratricide prevention + checkpoint resistance in CD7-CAR. Guideline: keep the combined concentration within 5-20 μM to avoid non-specific effects. Include appropriate controls: single knockdowns, non-targeting control, untreated. Validate each target individually before combining.
What is the optimal timing for ASO treatment during CAR-T manufacturing?
Timing depends on application goal: Pre-Transduction (Day 2-3 post-activation): For checkpoint knockdown (PD-1, CTLA-4, LAG-3), fratricide prevention (CD7, CD5 knockdown), or universal CAR-T strategies (HLA knockdown). Establishes phenotype before CAR introduction. Post-Transduction (Day 5-7): For exhaustion prevention (TOX, NR4A1 knockdown) or metabolic optimization. Ensures CAR expression established before modifying T cell state. Throughout manufacturing, re-dosing every 3 to 5 days: For sustained knockdown during entire 14-day expansion. Re-dosing compensates for ASO dilution during rapid cell division.
Does transient knockdown limit CAR-T efficacy compared to permanent CRISPR knockout?
No. For CAR-T research applications, transient knockdown offers key advantages: (1) Manufacturing Optimization: whether a transient knockdown during the 7-14 day expansion leaves a less exhausted phenotype behind after the ASO is diluted is the question this design asks, and the serial rechallenge assay is what answers it. (2) No Genome Editing: Avoids permanent genome editing and the off-target mutagenesis screening it requires. (3) Safety: Reversible modification reduces risk of unintended consequences from permanent gene disruption. (4) Flexibility: Can re-dose during expansion for sustained effect, or allow knockdown to wane post-manufacturing. For research applications validating CAR-T enhancement strategies before committing to CRISPR development, transient knockdown is enough.
How is this different from CRISPR knockout for CAR-T enhancement?
Both achieve gene silencing but with different mechanisms and tradeoffs: AUMsilence sdASO: Transient, reversible knockdown. No transfection, so no transfection-induced cell death. No genome editing (no off-target mutagenesis). Added to the medium. Fast (test in 2-3 weeks). Used for research, process optimization and proof-of-concept studies. CRISPR: Permanent knockout. Requires electroporation (reduced viability, phenotype changes). Genome editing (requires off-target screening). Complex delivery (guide RNA + Cas9 protein or mRNA). Slower (4-6 weeks for validation). Recommended workflow: Validate CAR-T enhancement strategy with AUMsilence sdASO first (fast, low-risk). If it holds, a permanent knockout with CRISPR is the next step.
Can I use AUMsilence sdASO with CAR-NK cells?
Yes. AUMsilence sdASO is used in CAR-NK cells (NK-92 cell line or primary NK cells expressing CARs). Same protocols apply: gymnotic delivery, 10 μM, 24-72 hours for knockdown. Applications: (1) Checkpoint modulation in CAR-NK (PD-1, TIGIT, NKG2A), (2) Enhance CAR-NK persistence and cytotoxicity, (3) Optimize CAR-NK manufacturing (NK-92 is off-the-shelf allogeneic platform). CAR-NK cells offer advantages: no GvHD risk (can be allogeneic), innate tumor targeting (CAR-independent NK cell receptors), potentially safer than CAR-T. Combining CAR-NK with AUMsilence sdASO checkpoint knockdown gives an allogeneic platform for checkpoint studies.
What controls should I include in CAR-T enhancement experiments?
Essential controls for rigorous CAR-T validation: (1) Untreated CAR-T: Gold standard; activate, transduce, expand without ASO. (2) Non-targeting control ASO: Same concentration and timing as experimental ASO; verifies target specificity. (3) Mock-transduced + ASO: T cells with ASO but no CAR; separates ASO effects from CAR-specific effects. (4) CAR expression verification: Protein L staining in all groups; ensures ASO does not affect CAR transgene. (5) Dose-response: Test 5 μM, 10 μM and 20 μM; confirms concentration-dependent knockdown. (6) Independent ASO sequences: Test 3-5 different ASOs targeting same gene; gold standard for specificity (concordant phenotypes = on-target). (7) Viability controls: 7-AAD or Live/Dead in all flow panels, read against the untreated arm. Include biological triplicates (different donors) for statistical power.
How much does AUMsilence sdASO improve CAR-T function?
Improvements vary by application, and the direction each knockdown takes is what published CAR-T studies report: Checkpoint knockdown (PD-1, CTLA-4, LAG-3): better tumor killing at low E:T ratios, longer persistence in serial rechallenge assays, less co-expression of exhaustion markers (PD-1+ TIM-3+ LAG-3+). Exhaustion prevention (TOX, NR4A1 knockdown): less checkpoint upregulation during expansion, more cytokine production (IFN-γ, TNF-α), better proliferation. Tumor microenvironment resistance (TGFβR2 knockdown): maintained function in TGF-β-supplemented cultures, improved solid tumor infiltration and persistence in xenograft models. Fratricide prevention (CD7/CD5 knockdown): CAR-T cells where a fratricide-prone CAR leaves none to expand. The size of any improvement depends on the tumor model, the CAR design and the protocol, so run pilot experiments and measure it.
Can I use AUMsilence sdASO to reduce cytokine release syndrome (CRS) risk?
Yes. Cytokine modulation strategies to mitigate CRS: (1) TNF-α knockdown: Reduces the CAR-T's own TNF contribution to CRS; perforin and granzyme are separate genes, and the killing assay reads whether cytotoxicity was kept. Test across 5-20 μM for the TNF ASO. (2) IL-6 knockdown: IL-6 drives severe CRS. While primarily macrophage-derived, the CAR-T's own contribution can be reduced. (3) Partial IFN-γ knockdown: Use a lower ASO concentration within 5-20 μM for a partial reduction; balances CRS risk with anti-tumor immunity (IFN-γ essential for efficacy). Validation: Measure cytokine secretion (ELISA) after tumor stimulation and read cytotoxicity against the untreated arm (target killing assays), consider in vivo CRS models (immunodeficient mice, measure serum cytokines post-CAR-T infusion). Important: CRS mitigation must not compromise anti-tumor efficacy. Dose-response experiments critical to find optimal balance.

Order, or talk to a scientist

AUMsilence sdASO is used on CAR-T persistence, on exhaustion during expansion and on the expansion protocol itself, with no transfection. A scientist reviews the target, the CAR design and the manufacturing stage before the order.

Order AUMsilence sdASOConsult our CAR-T experts

For research use only. Not for use in diagnostic or therapeutic procedures.